The risk for major adverse cardiovascular events (MACE) with targeted therapies for patients with advanced renal cell carcinoma (RCC) in real-world practice remains unclear. The aim of this study was to compare the risk for MACE associated with targeted cancer therapies with that associated with cytokine treatment in patients with advanced RCC.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Authors
Dong-Yi Chen, MD
Wen-Kuan Huang, MD, PHD
Lai-Chu See, PHD

Important Dates

Date of Release: June 21, 2022
Term of Approval/Date of CME/MOC/ECME Expiration: June 20, 2023